Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus

被引:114
作者
Ma, Chun-yan [1 ]
Jiao, Yu-lian [1 ]
Zhang, Jie [1 ]
Yang, Qing-rui [2 ]
Zhang, Zhi-fen [3 ]
Shen, Ya-juan [3 ]
Chen, Zi-jiang [1 ]
Zhao, Yue-ran [1 ]
机构
[1] Shandong Univ, Dept Cent Lab, Prov Hosp Affiliated, Jinan 250021, Peoples R China
[2] Shandong Univ, Dept Rheumatol, Prov Hosp Affiliated, Jinan 250021, Peoples R China
[3] Shandong Univ, Dept Lab Med, Prov Hosp Affiliated, Jinan 250021, Peoples R China
基金
中国国家自然科学基金;
关键词
Systemic lupus erythematosus; High-mobility group box protein 1; Interferon-alpha; Tumor necrosis factor-alpha; GROUP BOX CHROMOSOMAL-PROTEIN-1; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; CYTOKINE; INTERFERON; ACTIVATION; EXPRESSION; MEDIATOR; BINDING; HMG-1;
D O I
10.1007/s00296-010-1636-6
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Recent studies indicate that high-mobility group box protein 1 (HMGB1) contributes to the pathogenesis of diverse autoimmune disorders. It induces the production of interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF-alpha) in vitro. In the present study, plasma HMGB1, TNF-alpha, and IFN-alpha were determined with ELISA in 37 patients with systemic lupus erythematosus (SLE) and 39 age- and sex-matched healthy controls (HC). The possible associations of these cytokines with disease activities, autoantibodies, and certain laboratory parameters were also explored. The plasma levels of HMGB1, TNF-alpha, and IFN-alpha were increased in SLE patients compared with those of HC (P < 0.05). Moreover, the levels of HMGB1 and TNF-alpha in the active SLE patients were elevated compared with those in inactive patients and HC. Additionally, plasma HMGB1 was positively correlated with peripheral neutrophils, and plasma TNF-alpha was positively correlated with anti-Sm, ESR and CRP, while plasma IFN-alpha was inversely correlated with the age and platelet level in SLE patients. Our data indicated that increased plasma HMGB1 was associated with disease activity in SLE, which was similar to TNF-alpha. High level of plasma IFN-alpha may be related to nephritis and thrombocytopenia in SLE.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 39 条
[1]
Cutting edge: HMG-1 as a mediator of acute lung inflammation [J].
Abraham, E ;
Arcaroli, J ;
Carmody, A ;
Wang, HC ;
Tracey, KJ .
JOURNAL OF IMMUNOLOGY, 2000, 165 (06) :2950-2954
[2]
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes [J].
Andersson, U ;
Wang, HC ;
Palmblad, K ;
Aveberger, AC ;
Bloom, O ;
Erlandsson-Harris, H ;
Janson, A ;
Kokkola, R ;
Zhang, MH ;
Yang, H ;
Tracey, KJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (04) :565-570
[3]
The role of tumor necrosis factor-alpha in systemic lupus erythematosus [J].
Aringer, Martin ;
Smolen, Josef S. .
ARTHRITIS RESEARCH & THERAPY, 2008, 10 (01)
[4]
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood [J].
Bennett, L ;
Palucka, AK ;
Arce, E ;
Cantrell, V ;
Borvak, J ;
Banchereau, J ;
Pascual, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) :711-723
[5]
HMG proteins: dynamic players in gene regulation and differentiation [J].
Bianchi, ME ;
Agresti, A .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (05) :496-506
[6]
Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells [J].
Dumitriu, IE ;
Baruah, P ;
Bianchi, ME ;
Manfredi, AA ;
Rovere-Querini, P .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (07) :2184-2190
[7]
Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome [J].
Ek, Monica ;
Popovic, Karin ;
Harris, Helena Erlandsson ;
Naucler, Cecilia Soderberg ;
Wahren-Herlenius, Marie .
ARTHRITIS AND RHEUMATISM, 2006, 54 (07) :2289-2294
[8]
Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J].
Feldmann, M ;
Maini, RN .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :163-196
[9]
Induction of clinical autoimmune disease by therapeutic interferon-α [J].
Gota, C ;
Calabrese, L .
AUTOIMMUNITY, 2003, 36 (08) :511-518
[10]
Gröndal G, 2000, CLIN EXP RHEUMATOL, V18, P565